Cargando…

Modelling the effect of short-course multidrug-resistant tuberculosis treatment in Karakalpakstan, Uzbekistan

BACKGROUND: Multidrug-resistant tuberculosis (MDR-TB) is a major threat to global TB control. MDR-TB treatment regimens typically have a high pill burden, last 20 months or more and often lead to unsatisfactory outcomes. A 9–11 month regimen with seven antibiotics has shown high success rates among...

Descripción completa

Detalles Bibliográficos
Autores principales:	Trauer, James M., Achar, Jay, Parpieva, Nargiza, Khamraev, Atadjan, Denholm, Justin T., Falzon, Dennis, Jaramillo, Ernesto, Mesic, Anita, du Cros, Philipp, McBryde, Emma S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5114735/ https://www.ncbi.nlm.nih.gov/pubmed/27855693 http://dx.doi.org/10.1186/s12916-016-0723-2

Ejemplares similares

Outcomes with a shorter multidrug-resistant tuberculosis regimen from Karakalpakstan, Uzbekistan
por: du Cros, Philipp, et al.
Publicado: (2021)

Patient and health-care worker perspectives on the short-course regimen for treatment of drug-resistant tuberculosis in Karakalpakstan, Uzbekistan
por: Horter, Shona, et al.
Publicado: (2020)

Person-centred care in practice: perspectives from a short course regimen for multi-drug resistant tuberculosis in Karakalpakstan, Uzbekistan
por: Horter, Shona, et al.
Publicado: (2020)

Acquired bedaquiline resistance in Karakalpakstan, Uzbekistan
por: Nair, P., et al.
Publicado: (2022)

Primary bedaquiline resistance in Karakalpakstan, Uzbekistan
por: Moe, S., et al.
Publicado: (2023)

Where there is hope: a qualitative study examining patients’ adherence to multi-drug resistant tuberculosis treatment in Karakalpakstan, Uzbekistan
por: Horter, Shona, et al.
Publicado: (2016)

Multidrug-Resistant Tuberculosis in Child Successfully Treated with 9-Month Drug Regimen
por: Achar, Jay, et al.
Publicado: (2015)

Programme costs of longer and shorter tuberculosis drug regimens and drug import: a modelling study for Karakalpakstan, Uzbekistan
por: Kohler, Stefan, et al.
Publicado: (2022)

Assessment of dietary exposure to some persistent organic pollutants in the Republic of Karakalpakstan of Uzbekistan.
por: Muntean, Nigina, et al.
Publicado: (2003)

The contribution of drug import to the cost of tuberculosis treatment: A cost analysis of longer, shorter, and short drug regimens for Karakalpakstan, Uzbekistan
por: Kohler, Stefan, et al.
Publicado: (2022)

2389. Surveillance evaluation of COVID-19 pharmacovigilance—Karakalpakstan, Uzbekistan, 2022
por: Tursinov, Yunis, et al.
Publicado: (2023)

Multidrug-Resistant Tuberculosis Treatment Outcomes in Karakalpakstan, Uzbekistan: Treatment Complexity and XDR-TB among Treatment Failures
por: Cox, Helen S., et al.
Publicado: (2007)

Treatment Compliance of Multidrug Resistant Tuberculosis in Uzbekistan: Does Practice Follow Policy?
por: Usmanova, Ruzilya, et al.
Publicado: (2021)

Factors Associated with Unfavourable Treatment Outcomes in Patients with Tuberculosis: A 16-Year Cohort Study (2005–2020), Republic of Karakalpakstan, Uzbekistan
por: Gadoev, Jamshid, et al.
Publicado: (2021)

High rates of multidrug-resistant and rifampicin-resistant tuberculosis among re-treatment cases: where do they come from?
por: Ragonnet, Romain, et al.
Publicado: (2017)

Hospitalizations and Treatment Outcomes in Patients with Urogenital Tuberculosis in Tashkent, Uzbekistan, 2016–2018
por: Ismatov, Bakhtiyor, et al.
Publicado: (2021)

Characteristics and Treatment Outcomes of Patients with Tuberculosis Receiving Adjunctive Surgery in Uzbekistan
por: Riskiyev, Anvar, et al.
Publicado: (2021)

Genetic Polymorphism of 27 Y-STR Loci in the Western Kazakh Tribes from Kazakhstan and Karakalpakstan, Uzbekistan
por: Ashirbekov, Yeldar, et al.
Publicado: (2022)

Adverse Drug Reactions among Children with Tuberculosis in Tashkent, Uzbekistan, 2019
por: Abdusalomova, Makhliyo, et al.
Publicado: (2021)

Health system support and health system strengthening: two key facilitators to the implementation of ambulatory tuberculosis treatment in Uzbekistan
por: Kohler, Stefan, et al.
Publicado: (2016)

A novel Bayesian geospatial method for estimating tuberculosis incidence reveals many missed TB cases in Ethiopia
por: Shaweno, Debebe, et al.
Publicado: (2017)

The role of geospatial hotspots in the spatial spread of tuberculosis in rural Ethiopia: a mathematical model
por: Shaweno, Debebe, et al.
Publicado: (2018)

Universal Access to Xpert MTB/RIF Testing for Diagnosis of Tuberculosis in Uzbekistan: How Well Are We Doing?
por: Turaev, Laziz, et al.
Publicado: (2021)

Off-Label Use of Bedaquiline in Children and Adolescents with Multidrug-Resistant Tuberculosis
por: Achar, Jay, et al.
Publicado: (2017)

Treatment Outcomes of Isoniazid-Resistant (Rifampicin Susceptible) Tuberculosis Patients in Uzbekistan, 2017–2018
por: Sayfutdinov, Zayniddin, et al.
Publicado: (2021)

Trends, Characteristics and Treatment Outcomes of Patients with Drug-Resistant Tuberculosis in Uzbekistan: 2013–2018
por: Safaev, Khasan, et al.
Publicado: (2021)

Operational Research to Inform Programmatic Approaches to the Management of Tuberculosis in Uzbekistan
por: Gadoev, Jamshid, et al.
Publicado: (2021)

MON-322 The Characteristic of Reproductive Disorders in Women with ACTH-Dependent Cushing Syndrome in the Republic of Uzbekistan (RUz) and Republic of Karakalpakstan (RKK)
por: Khalimova, Zamira Yusufovna, et al.
Publicado: (2020)

Diagnostic Procedures, Diagnoses, and Treatment Outcomes of Patients with Presumptive Tuberculosis Pleural Effusion in Uzbekistan
por: Abdugapparov, Fazlkhan, et al.
Publicado: (2021)

A user-friendly mathematical modelling web interface to assist local decision making in the fight against drug-resistant tuberculosis
por: Ragonnet, Romain, et al.
Publicado: (2017)

Factors Associated with Unfavorable Treatment Outcomes in New and Previously Treated TB Patients in Uzbekistan: A Five Year Countrywide Study
por: Gadoev, Jamshid, et al.
Publicado: (2015)

Outcomes of HIV-infected versus HIV-non-infected patients treated for drug-resistance tuberculosis: Multicenter cohort study
por: Bastard, Mathieu, et al.
Publicado: (2018)

Risk Factors for Unfavorable Treatment Outcomes among the Human Immunodeficiency Virus-Associated Tuberculosis Population in Tashkent City, Uzbekistan: 2013–2017
por: Massavirov, Sherali, et al.
Publicado: (2021)

Recurrent tuberculosis and associated factors: A five - year countrywide study in Uzbekistan
por: Gadoev, Jamshid, et al.
Publicado: (2017)

Scaling Up Molecular Diagnostic Tests for Drug-Resistant Tuberculosis in Uzbekistan from 2012–2019: Are We on the Right Track?
por: Yuldashev, Sharofiddin, et al.
Publicado: (2021)

Vaccination Programs for Endemic Infections: Modelling Real versus Apparent Impacts of Vaccine and Infection Characteristics
por: Ragonnet, Romain, et al.
Publicado: (2015)

The use of anti-tuberculosis therapy for latent TB infection
por: Denholm, Justin T, et al.
Publicado: (2010)

Management of Latent Tuberculosis Infections in Australia and New Zealand: A Review of Current Practice
por: Denholm, Justin T., et al.
Publicado: (2010)

Risk Factors Associated with Default from Multi- and Extensively Drug-Resistant Tuberculosis Treatment, Uzbekistan: A Retrospective Cohort Analysis
por: Lalor, Maeve K., et al.
Publicado: (2013)

Incidence Rate and Risk Factors for Tuberculosis among People Living with HIV: A 2015–2017 Cohort from Tashkent, Uzbekistan
por: Sadirova, Dilbar, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_mjmkrrsp8onugao5mn7jlf5lvp